Blood Test Spots Small Breast Tumors With 95% Accuracy in Early Study

A blood test wouldn't need to find a tumor in an image at all. It's a fundamentally different detection route.

What did the researchers actually do?

The team worked in two stages:

• First, they examined tumors removed from 12 women to map the chemical marks that control gene use.
• Second, they studied blood samples from 77 women with breast cancer and 30 women without it, then used computer models to classify the samples.

Those models flagged early breast cancer at 95% accuracy, catching tumors measuring no more than two centimeters — small enough that mammograms sometimes miss them.

The researchers also checked a larger collection of patient samples. The test performed across different breast cancer types, and breast density did not strongly affect the results. That last point matters, because dense tissue is one of mammography's biggest blind spots.

Why does the recurrence finding matter?

Inside tumors that doctors label relatively low risk, the team found signs of unusually aggressive cancer cells. Standard assessments can overlook them.

Blood patterns tied to those aggressive cells predicted which patients would later see their cancer return — the 81% accuracy figure. If that holds up in larger studies, the test could help spare low-risk patients from overtreatment while flagging others for tighter monitoring.

That's the hope. It is not yet the evidence.

Is the test ready for doctors to use?

No. The study has real limitations, and the researchers say so plainly.

The patient groups were limited in size, and the samples came from selected groups — not from large populations of healthy people. That means the study can't show how often the test would miss cancer or raise false alarms when deployed at scale. Those numbers, from independent studies, must come first.

For now, mammograms and established medical advice remain essential. If you're due for screening, keep the appointment.

The blood test is a promising research direction, not a product. It points toward a future where a simple draw could complement mammography — especially for women with dense breasts — and where survivors could learn their recurrence risk from a vial rather than guesswork. Getting there will take years of further trials.

The takeaway: a blood test spotted small breast tumors at 95% accuracy and predicted recurrence at 81% in early Israeli research — encouraging numbers that still need large, independent confirmation.